References
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
- Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP); consensus on terminology by international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737–740.
- Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128–1132.
- Nazha A, Estrov Z, Cortes J, et al. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma 2013;54:2537–2539.
- Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008;111:1862–1865.
- Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7:e35631.
- Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings: clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006;85:226–232.
- Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007;21:2420–2427.
- Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;8:2239–2241.
- Kröger N, Zabelina T, van Biezen A, et al.; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 2011;96:291–297.
- Avcı Z, Malbora B, Gülşan M, et al. Acute massive myelofibrosis with acute lymphoblastic leukemia. Turk J Hematol 2009:26;204–206.
- Tadmor T, Shvidel L, Aviv A, et al. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: A study of 176 patients with prognostic implications. Cancer 2013 Feb 19. [Epub ahead of print]
- Ettrup MS, Jensen AØ, Engebjerg MC, et al. Bone marrow reticulin and collagen content in patients with adult chronic immune thrombocytopenic purpura: a Danish nation wide study. Am J Hematol 2010;85:930–934.
- Verstovsek S, Mesa RA, Rhoades S, et al. Phase I study of the JAK2 V617F inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2011;118(Suppl. 1): Abstract 2814.
- Santos F, Verstovsek S. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?Curr Opin Hematol 2013;20: 123–129.
- Tadmor T, Bejar J, Attias D, et al. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms. Am J Hematol 2013 Feb 8. [Epub ahead of print]
- Kröger N, Kvasnicka M, Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair 2012;5(Suppl. 1):S25.